Amphastar Pharmaceuticals (NASDAQ:AMPH) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Tuesday.
Other equities analysts also recently issued research reports about the company. Zacks Investment Research downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 27th. Raymond James Financial downgraded Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 price objective on the stock. in a research report on Thursday, November 9th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Amphastar Pharmaceuticals in a research report on Sunday, September 17th. BMO Capital Markets upped their price objective on Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the company a “market perform” rating in a research report on Friday, November 10th. Finally, Needham & Company LLC upped their price objective on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $19.50.
Shares of Amphastar Pharmaceuticals (NASDAQ AMPH) opened at $18.03 on Tuesday. Amphastar Pharmaceuticals has a twelve month low of $12.05 and a twelve month high of $19.95. The firm has a market capitalization of $828.94, a price-to-earnings ratio of 120.40, a P/E/G ratio of 1.27 and a beta of 1.69. The company has a current ratio of 3.08, a quick ratio of 1.86 and a debt-to-equity ratio of 0.13.
In other news, Director Stephen B. Shohet sold 7,862 shares of the stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $18.04, for a total transaction of $141,830.48. Following the transaction, the director now owns 31,978 shares of the company’s stock, valued at approximately $576,883.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO William J. Peters sold 3,026 shares of the stock in a transaction on Friday, October 13th. The stock was sold at an average price of $18.56, for a total value of $56,162.56. The disclosure for this sale can be found here. Insiders sold a total of 92,060 shares of company stock worth $1,716,956 in the last ninety days. 11.10% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP bought a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter worth $400,000. Argent Capital Management LLC grew its position in shares of Amphastar Pharmaceuticals by 102.6% during the 3rd quarter. Argent Capital Management LLC now owns 121,275 shares of the company’s stock worth $2,167,000 after buying an additional 61,425 shares in the last quarter. Cornerstone Capital Management Holdings LLC. grew its position in shares of Amphastar Pharmaceuticals by 1.8% during the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 283,200 shares of the company’s stock worth $5,060,000 after buying an additional 5,000 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Amphastar Pharmaceuticals by 17.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,558,113 shares of the company’s stock worth $27,844,000 after buying an additional 226,271 shares in the last quarter. Finally, Nordea Investment Management AB grew its position in shares of Amphastar Pharmaceuticals by 11.6% during the 3rd quarter. Nordea Investment Management AB now owns 129,046 shares of the company’s stock worth $2,306,000 after buying an additional 13,439 shares in the last quarter. 44.14% of the stock is currently owned by institutional investors and hedge funds.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
What are top analysts saying about Amphastar Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amphastar Pharmaceuticals and related companies.